<p>Filgrastim is indicated to those:</p>

<ul>
	<li>Cancer patients receiving myelosuppressive chemotherapy</li>
	<li>Patients with Acute Myeloid Leukemia receiving induction or consolidation chemotherapy</li>
	<li>Cancer patients receiving bone marrow transplant</li>
	<li>Patients with severe neutropenia</li>
	<li>Peripheral blood progenitor cell collection and therapy</li>
</ul>

<p>Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology. G-CSF regulates the production of neutrophils within the bone marrow and affects neutrophil progenitor proliferation, differentiation and enhances phagocytic activity.</p>